BackgroundIVD is a key enzyme in leucine catabolism, catalyzing the conversion of isovaleryl-CoA to 3-methylcrotonyl-CoA.

Two key protein structures in the body are being visualized for the first time, thanks in part to the latest technology in ...

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for ...

Lithium-metal batteries have not hit the market yet, but if they do, they could be a solution to the everyday woes of the ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

In this week’s Science for All newsletter, Manaswini Vijayakumar breaks down an experiment that allowed scientists to see the ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

In this week’s Science for All newsletter, Manaswini Vijayakumar breaks down an experiment that allowed scientists to see the ...

The model enables the study of the fundamental interactions that underlie neurodegenerative disease. Researchers from Northwestern University and the University of California, Santa Barbara have ...

Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research ...